Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

Summary

This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II trial of twelve weeks of KBP-042 administered as daily s.c. injections in subjects with Type 2 Diabetes Mellitus with inadequate glycaemic control while treated with a stable dose of metformin. The trial is planned to be performed in Czech Republic, Denmark, Moldova, Poland, Romania and United Kingdom

Timeline

Start

2017-08-23

Primary completion

2018-07-09

Completion

2018-07-31

Drugs

Indications